BioMarin Pharmaceuticals Inc(BMRN)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

BMRN iron condor setups BMRN expected move BMRN IV rank history BMRN Fibonacci levels BMRN insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

BMRN $62.21 —
Snapshot
$62.21
52-Week Range
$49.26 – $70.98
YTD
+4.64%
IV Rank (30D)
57.15
Straddle Price
$4.50
P/C Vol Ratio
0.39
Market Cap
$12.3B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.01%
Beta vs SPY0.73
Cost of Equity (CAPM)8.64% (VRP-adj)
WACC7.90%
Volatility Risk Premium+47.7pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+27.5%
DCF Horizon12 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.7B
Return on Equity (TTM)1.1%
Book / Price51.1% — banking bias active (P/B is primary)
Gross Margin (TTM)76.1%
FCF Margin (TTM)21.7%
Debt / Equity0.56
Quality Score4/6 — high quality (12y DCF)
Market-Implied Growth+3.6% (reverse-DCF on current price)
SMA 50$63.86 (Market Anchor value)
SMA 20 / Bollinger Mid$65.20
Bollinger Width / SMA208.8% (drives anchor stability)
Net Debt$2.7B
Market Cap$12B
Peers used for multiples: BIIB, REGN, UTHR (filtered from 8 ETF-co-members; sector bias active)
Model Conviction
73%
20-Day Fair Value
≈ by Oct 22, 2026
$64.87
α +4.3% rank 77%
40-Day Fair Value
≈ by Nov 20, 2026
$69.32
α +11.4% rank 86%
60-Day Fair Value
≈ by Dec 21, 2026
$68.93
α +10.8% rank 90%
MethodImplied PriceWeightDetail
DCF $356.05 20%
DDM (Gordon) n/a 0%
Peer P/E $7.60 5% median 18.7× · 3 peers
Peer EV/EBITDA $15.31 6% median 16.8× · 3 peers
Peer P/B $82.50 8% median 2.5× · 3 peers
Peer P/S $99.73 8% median 5.2× · 3 peers
Market Anchor (SMA50) $63.86 39% stability 100% (BB-width)
Options Expected (B-L 30d) $65.61 15% 15 strikes · skew +0.99
As of 2026-09-23 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$12.3B

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +1.03% 23
Feb -1.02% 23
Mar -0.57% 23
Apr +0.51% 23
May +1.10% 23
Jun +2.32% 23
Jul +4.67% 23
Aug +0.44% 23
Sep -3.32% 24
Oct -2.83% 23
Nov +6.85% 23
Dec +5.10% 23
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $65.00
SMA 50: $63.94
SMA 200: $58.45
Current: $62.21
EMA 12: $64.33
EMA 26: $64.62
MACD: -0.2847 | Signal: -0.4640
BULLISH
ADX (14): 14.29
RANGE
+DI: 16.53
−DI: 30.10

Momentum Oscillators

RSI (14): 39.34
NEUTRAL
Stoch %K: 7.52
Stoch %D: 11.21
Williams %R: -89.70

Volume & Volatility

BB Upper: $67.24
BB Lower: $62.77
OVERSOLD
OBV: 36,964,181
Vol SMA 20: 1,952,400
Vol ROC: 7.98%
ATR: $1.71
True Range: $2.42
HV 20: 23.6%
HV 30: 26.3%
HV 60: 29.6%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-25T00:00:00 – 2026-09-23T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL with confidence level (6/10)

Key Drivers:

  • Strong technical momentum signals from MACD and RSI
  • Positive news sentiment from recent headlines on Duchenne Muscular Dystrophy clinical trial pipeline and BioMarin's dwarfism study data

Primary Risks:

  • Recent price action may be driven by speculative buying, potentially unsustainable in the long term
  • IV premium vs HV30 indicates implied volatility richer than realized, suggesting potential for mean reversion

Investment Thesis: BioMarin (BMRN) has been experiencing a strong technical uptrend, supported by positive news sentiment and low volatility. While this could continue short-term, there are concerns about the sustainability of the price action and the potential for mean reversion in implied volatility.

Recent News Sentiment Impact: The recent headlines have contributed to a positive sentiment around BioMarin's clinical trial pipeline advancements and dwarfism study data. This has likely driven some buying pressure and supported the stock's technical momentum.

Technical Analysis

Trend Direction: Short-term (1-4 weeks) - Bullish, Medium-term (1-3 months) - Neutral, Long-term (3-12 months) - Bullish

Support/Resistance Levels:

  • Upper Bollinger Band: $58.40
  • Middle Line (SMA 20): $55.80
  • Lower Bollinger Band: $53.20

Momentum Signals:

  • RSI (14): 59.00 (neutral)
  • MACD: 0.66 / Signal: 0.13 / Histogram: 0.53 (bullish)

Volume Analysis: Volume trends and institutional interest signals:

  • On-Balance Volume (OBV): 20776878.88
  • Volume Rate of Change: 29.02%

News & Sentiment Analysis

Recent Headlines Summary:

The recent headlines have been predominantly positive, highlighting advancements in BioMarin's clinical trial pipeline and study data on dwarfism.

Sentiment Assessment: Aggregate news sentiment is POSITIVE.

Catalyst Identification: Upcoming events include the company's continued efforts to advance its clinical trial pipeline and potential regulatory approvals.

Market Narrative: The recent headlines have likely driven buying pressure, supporting the stock's technical momentum. This narrative aligns with the short-term bullish trend direction.

Risk & Volatility Assessment

Beta Interpretation: Beta 0.47 (low volatility - stock moves less than market)

Volatility Regime: Current vs historical volatility levels:

  • Historical Volatility: HV20 42.3% / HV30 44.4% / HV60 37.0%
  • IV Premium vs HV30: 30.2% (positive = implied richer than realized)

Options Market Signals:

  • IV Rank: 30.4% (Medium - shows if volatility is historically high/low)
  • Current IV: 57.8%
  • Expected Move: $3.65 (22 DTE), 7-DTE: $3.65

Market Context & Positioning

Sector Performance: Relative strength vs sector/market:

  • BioMarin's performance has been stronger than the broader biotech sector and market.

Institutional Activity: Volume patterns suggesting institutional interest signals:

  • Institutional buying pressure is present, with volume increasing on up days.

Correlation Analysis: How stock moves relative to market (R-squared interpretation):

  • Correlation: 0.17

Key Levels & Action Items

Critical Price Levels:

  • Upper Bollinger Band: $58.40
  • Middle Line (SMA 20): $55.80
  • Lower Bollinger Band: $53.20

Breakout/Breakdown Levels: Technical levels that could trigger significant moves:

  • SMA 50: $54.37
  • EMA 12: $56.07

Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:

  • No earnings data available.

Risk Management: Stop-loss levels and position sizing considerations:

  • Consider setting a stop-loss around the lower Bollinger Band ($53.20) to manage risk.
  • Position sizing should be adjusted based on individual risk tolerance and market conditions.

Please note that this report provides an objective analysis of BioMarin's stock performance, technical indicators, news sentiment, and options activity. It does not include a buy or sell recommendation. The confidence level is 6/10 due to the potential risks and uncertainties surrounding the company's clinical trial pipeline and regulatory approvals.

Generated
Earnings History
7 of 8 under expected move
Avg Expected Move
8.67%
Avg Actual Move
4.57%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-10-29 After-Close 7.72% 4.20% 0.54x Within
2025-02-19 After-Close 8.10% 3.17% 0.39x Within
2025-05-01 After-Close 7.45% 1.15% 0.15x Within
2025-08-04 After-Close 10.09% 3.49% 0.35x Within
2025-10-27 After-Close 11.53% 0.94% 0.08x Within
2026-01-12 After-Close 4.99% 4.87% 0.98x Within
2026-05-04 After-Close 10.14% 3.71% 0.37x Within
2026-08-06 After-Close 9.31% 15.03% 1.61x Exceeded
Options Activity
IV Rank (30D)
57.15
IV Rank (7D)
57.15
Avg IV
67.1%
Straddle (30D)
$4.50
Straddle (7D)
$4.50
P/C Volume
0.39
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.42
Correlation (SPY)
15.7%
R²
0.02
Ann. Volatility
35.1%
SPY Volatility
13.0%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 195,391,000 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

595 filers797,138,595 shares$12.52B value407.97% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 32,073,212 $1.18B 9.43% 16.41% 2026-06-30
2 VANGUARD GROUP INC Custodian 18,127,847 $1.08B 8.60% 9.28% 2025-12-31
3 DODGE & COX 14,844,930 $849.43M 6.78% 7.60% 2026-06-30
4 PRIMECAP MANAGEMENT CO/CA/ 14,190,183 $811.96M 6.48% 7.26% 2026-06-30
5 VANGUARD CAPITAL MANAGEMENT LLC 8,743,633 $500.31M 4.00% 4.47% 2026-06-30
6 VANGUARD PORTFOLIO MANAGEMENT LLC 8,648,678 $494.88M 3.95% 4.43% 2026-06-30
7 NORGES BANK 8,207,954 $469.66M 3.75% 4.20% 2026-06-30
8 STATE STREET CORP (STT, STT-PG) 22,966,959 $461.15M 3.68% 11.75% 2026-06-30
9 VIKING GLOBAL INVESTORS LP 7,616,563 $435.82M 3.48% 3.90% 2026-06-30
10 Vestal Point Capital, LP 6,025,000 $344.75M 2.75% 3.08% 2026-06-30
11 AQR CAPITAL MANAGEMENT LLC Custodian 5,699,541 $322.54M 2.58% 2.92% 2026-06-30
12 FMR LLC Custodian 4,822,893 $275.97M 2.20% 2.47% 2026-06-30
13 DIMENSIONAL FUND ADVISORS LP Custodian 4,075,714 $233.22M 1.86% 2.09% 2026-06-30
14 GEODE CAPITAL MANAGEMENT, LLC Custodian 3,911,794 $223.89M 1.79% 2.00% 2026-06-30
15 Capital Research Global Investors 3,504,387 $200.52M 1.60% 1.79% 2026-06-30
16 Deep Track Capital, LP 3,307,481 $189.25M 1.51% 1.69% 2026-06-30
17 MILLENNIUM MANAGEMENT LLC Custodian 2,071,816 $118.55M 0.95% 1.06% 2026-06-30
18 TENOR CAPITAL MANAGEMENT Co., L.P. 111,500,000 $108.89M 0.87% 57.07% 2026-06-30
19 Assenagon Asset Management S.A. 1,762,086 $100.83M 0.81% 0.90% 2026-06-30
20 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,616,020 $92.47M 0.74% 0.83% 2026-06-30
21 FIRST TRUST ADVISORS LP 1,606,273 $91.91M 0.73% 0.82% 2026-06-30
22 NORTHERN TRUST CORP Custodian 1,558,104 $89.15M 0.71% 0.80% 2026-06-30
23 MORGAN STANLEY Custodian 3,076,989 $87.64M 0.70% 1.57% 2026-06-30
24 Jones Hill Capital LP 1,431,590 $81.92M 0.65% 0.73% 2026-06-30
25 DEERFIELD MANAGEMENT COMPANY, L.P. 1,332,836 $76.26M 0.61% 0.68% 2026-06-30
19 filers$118.36M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $54.48M 46.03% 2026-06-30
2 CITADEL ADVISORS LLC Custodian $13.19M 11.14% 2026-06-30
3 Walleye Trading LLC $6.55M 5.54% 2026-06-30
4 JANE STREET GROUP, LLC Custodian $6.28M 5.30% 2026-06-30
5 SIMPLEX TRADING, LLC Custodian $4.82M 4.08% 2026-06-30
6 IMC-Chicago, LLC Custodian $4.75M 4.02% 2026-06-30
7 UBS Group AG Custodian $4.50M 3.80% 2026-06-30
8 WOLVERINE TRADING, LLC Custodian $4.37M 3.69% 2025-09-30
9 GROUP ONE TRADING LLC Custodian $3.35M 2.83% 2026-06-30
10 Stonepine Capital Management, LLC $3.12M 2.64% 2026-06-30
11 CITIGROUP INC Custodian $3.09M 2.61% 2026-06-30
12 Caption Management, LLC $2.86M 2.42% 2026-06-30
13 MILLENNIUM MANAGEMENT LLC Custodian $2.40M 2.03% 2026-06-30
14 Greenland Capital Management LP $2.29M 1.93% 2026-06-30
15 Jefferies Financial Group Inc. $858.30K 0.73% 2026-06-30
16 Walleye Capital LLC $812.52K 0.69% 2026-06-30
17 TUDOR INVESTMENT CORP ET AL $526.42K 0.44% 2026-06-30
18 INSPIRION WEALTH ADVISORS, LLC $57.82K 0.05% 2026-06-30
19 Raiffeisen Bank International AG $39.83K 0.03% 2026-06-30
11 filers$41.17M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $24.04M 58.38% 2026-06-30
2 Caption Management, LLC $4.01M 9.73% 2026-06-30
3 CITIGROUP INC Custodian $3.09M 7.50% 2026-06-30
4 CITADEL ADVISORS LLC Custodian $2.87M 6.96% 2026-06-30
5 Walleye Trading LLC $2.32M 5.63% 2026-06-30
6 IMC-Chicago, LLC Custodian $1.98M 4.81% 2026-06-30
7 WOLVERINE TRADING, LLC Custodian $1.46M 3.56% 2025-09-30
8 JANE STREET GROUP, LLC Custodian $726.69K 1.76% 2026-06-30
9 SIMPLEX TRADING, LLC Custodian $286.10K 0.69% 2026-06-30
10 Walleye Capital LLC $234.60K 0.57% 2026-06-30
11 GROUP ONE TRADING LLC Custodian $165.94K 0.40% 2026-06-30
Insider Activity
Latest: 2026-09-14
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-14 Robert M Plenge Director Award (A) +6,140 — EDGAR
2026-09-03 George Eric Davis EVP, Chief Legal Officer Sell (S) −17,557 $66.28 -$1.16M EDGAR
2026-06-04 ELIZABETH M ANDERSON Director Award (A) +7,490 — EDGAR
2026-06-04 Barbara W. Bodem Director Award (A) +7,490 — EDGAR
2026-06-04 IAN T CLARK Director Award (A) +7,490 — EDGAR
2026-06-04 Willard H Dere Director Award (A) +7,490 — EDGAR
2026-06-04 Mark J Enyedy Director Award (A) +7,490 — EDGAR
2026-06-04 ROBERT J. HOMBACH Director Award (A) +7,490 — EDGAR
2026-06-04 Maykin Ho Director Award (A) +7,490 — EDGAR
2026-06-04 Timothy P Walbert Director Award (A) +7,490 — EDGAR
2026-06-04 Athena Countouriotis Director Award (A) +7,490 — EDGAR
2026-05-21 Cristin Hubbard EVP, Chief Commercial Officer Tax (F) −2,318 $50.20 -$116.4K EDGAR
2026-05-11 Gregory R Friberg EVP, Chief R&D Officer Sell (S) −3,281 $53.85 -$176.7K EDGAR
2026-03-19 Alexander Hardy Chief Executive Officer Tax (F) −4,252 $56.05 -$238.3K EDGAR
2026-03-19 Brian Mueller EVP, Chief Financial Officer Tax (F) −2,117 $56.05 -$118.7K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
42 insiders · @ $62.21
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 JEAN JACQUES BIENAIME Director 473,892 $29.48M -$241.37M 336 2024-05-21
2 Alexander Hardy Chief Executive Officer 214,635 $13.35M $0 7 2026-03-19
3 ROBERT BAFFI President, Global Mfg/Tech Ops 189,020 $11.76M -$40.09M 90 2020-03-24
4 HENRY J FUCHS President, Worldwide R&D 185,074 $11.51M -$62.29M 112 2024-09-17
5 STEVE ASELAGE EVP, Chief Business Officer 154,375 $9.60M -$13.49M 33 2012-07-05
6 RICHARD A MEIER Director 127,426 $7.93M -$2.72M 39 2025-05-22
7 Brian Mueller EVP, Chief Financial Officer 123,314 $7.67M -$13.92M 82 2026-03-19
8 ELAINE J HERON Director 97,720 $6.08M -$8.48M 34 2024-06-04
9 Charles Greg Guyer EVP, Chief Technical Officer 84,140 $5.23M -$2.95M 22 2026-03-19
10 Jeffrey Robert Ajer EVP, Chief Commercial Officer 66,767 $4.15M -$27.45M 102 2024-05-06
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-05-07
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-05-07 Friberg Gregory R Officer 3,281 $176.7K 2026-05-07 Fidelity Brokerage Services LLC — EDGAR
2026-03-11 Guyer Charles Greg Officer 16,486 $996.7K 2026-03-11 Fidelity Brokerage Services LLC — EDGAR
2026-02-26 Friberg Gregory R Officer 6,326 $381.9K 2026-02-26 Fidelity Brokerage Services LLC — EDGAR
2026-02-26 Davis George Eric Officer 26,061 $1.60M 2026-02-26 Fidelity Brokerage Services LLC — EDGAR
2025-05-20 Burkhart Erin Officer 1,786 $105.9K 2025-05-20 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2025-05-02 Hubbard Cristin Officer 273 $17.7K 2025-05-02 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2025-03-19 Burkhart Erin Officer 1,295 $92.6K 2025-03-19 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2025-03-06 Guyer Charles Greg Officer 7,034 $501.4K 2025-03-06 Fidelity Brokerage Services LLC — EDGAR
2025-02-24 Burkhart Erin Officer 1,344 $91.9K 2025-02-24 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2024-11-12 Guyer Charles Greg Officer 5,278 $350.3K 2024-11-12 Fidelity Brokerage Services LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
Recent SEC Filings
Latest: 2026-06-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-06-04 0001628280-26-040812 EDGAR
2026-05-04 0001048477-26-000006 EDGAR
2026-04-27 0001193125-26-179243 EDGAR
2026-04-23 0001193125-26-173770 EDGAR
2026-03-16 0001193125-26-107314 EDGAR
2026-02-23 0001048477-26-000002 EDGAR
2026-02-12 0001193125-26-048736 EDGAR
2026-01-29 0001193125-26-029401 EDGAR
2026-01-26 0001193125-26-021718 EDGAR
2026-01-12 0001193125-26-010508 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-26 0001048477-26-000004 EDGAR
2025-02-24 0001048477-25-000007 EDGAR
2024-02-26 0001048477-24-000016 EDGAR
2023-02-27 0001048477-23-000009 EDGAR
2022-02-25 0001048477-22-000012 EDGAR
2021-02-26 0001048477-21-000008 EDGAR
2020-02-27 0001048477-20-000009 EDGAR
2019-02-28 0001564590-19-005033 EDGAR
2018-02-26 0001564590-18-003114 EDGAR
2017-02-27 0001564590-17-002483 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-05-05 0001048477-26-000008 EDGAR
2025-10-28 0001048477-25-000107 EDGAR
2025-08-05 0001048477-25-000090 EDGAR
2025-05-02 0001048477-25-000051 EDGAR
2024-10-31 0001048477-24-000152 EDGAR
2024-08-05 0001048477-24-000126 EDGAR
2024-04-26 0001048477-24-000070 EDGAR
2023-11-02 0001048477-23-000044 EDGAR
2023-08-02 0001048477-23-000029 EDGAR
2023-04-28 0001048477-23-000020 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/E Ratio168.1
P/B Ratio2.0
P/S Ratio3.6
EV/EBITDA51.4
TTM Revenue$3.4B
TTM Net Income$0.1B
TTM EPS$0.37
ROE1.1%
Debt/Equity0.66